Cleveland OH 克罗恩病临床试验
19项针对 克罗恩病的研究正在 Cleveland及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
招募中3 期
- Great Lakes Gastroenterology Research, LLC ( Site 5016), Mentor · 距离 22 英里
Investigating the Effect of the Non-nutritive Sweetener Sucralose in Inflammatory Bowel Disease
招募中欢迎健康志愿者
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center, Chagrin Falls · 距离 17 英里
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
招募中4 期
- Great Lakes Gastroenterology Research, LLC, Mentor · 距离 22 英里
Non-nutritive Sweeteners in Inflammatory Bowel Disease
招募中欢迎健康志愿者
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center, Chagrin Falls · 距离 17 英里
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
招募中2 期
- Great Lakes Gastroenterology Research, LLC, Mentor · 距离 22 英里
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
招募中3 期
- Great Lakes Gastroenterology Research, LLC, Mentor · 距离 22 英里
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
招募中3 期
- University Hospitals Cleveland Medical Center-Site Number: 8400073, Cleveland
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
招募中3 期
- Cleveland Clinic - Cleveland /ID# 256453, Cleveland
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
招募中4 期
- Great Lakes Gastroenterology Research, LLC, Mentor · 距离 22 英里
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
招募中3 期
- Great Lakes Gastroenterology Research, LLC, Mentor · 距离 22 英里
Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
招募中
- Cleveland Clinic, Cleveland
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
招募中3 期
- UH Cleveland Medical Center /ID# 262188, Cleveland
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
招募中3 期
- University Children's Clinic, Cleveland
- Cleveland Clinic, Cleveland
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
招募中4 期
- UH/Rainbow Babies and Children's Hospital, Cleveland
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
招募中3 期
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
Precise Infliximab Exposure and Pharmacodynamic Control
招募中2/3 期
- Cleveland Clinic Children's Hospital, Cleveland
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
招募中3 期
- University Hospitals Cleveland Medical Center, Cleveland
Treatment of Moderate to Severe Refractory Crohn's Disease
招募中1/2 期
- Cleveland Clinic, Cleveland
Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy
招募中观察性研究
- Cleveland Clinic Foundation, Cleveland
其他城市的 克罗恩病试验
- New York City, NY35 项研究
- Boston, MA19 项研究
- Miami, FL19 项研究
- St. Louis, MO19 项研究
- Tyler, TX17 项研究
- Houston, TX17 项研究
- Orlando, FL17 项研究
- Atlanta, GA17 项研究
- San Antonio, TX15 项研究
- San Diego, CA15 项研究
- Los Angeles, CA15 项研究
- Colorado Springs, CO13 项研究
Cleveland的其他研究
- 非小细胞肺癌43 项研究
- 癌症（所有类型）36 项研究
- 乳腺癌35 项研究
- 前列腺癌34 项研究
- 心力衰竭33 项研究
- 卵巢癌30 项研究
- 转移性癌症30 项研究
- 肺癌26 项研究
- 结直肠癌24 项研究
- 心血管疾病22 项研究
- 子宫内膜癌20 项研究
- 急性髓系白血病20 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。